23andMe, with support from The Michael J. Fox Foundation for Parkinson’s Research, conducted the world’s largest study on LRRK2 G2019S and uncovered new insights into the variant. 23andMe launched the Parkinson’s Impact Project, PIP, in 2018 to better understand which LRRK2 G2019S carriers’ are at greatest risk of developing Parkinson’s disease. The 3.5-year longitudinal study included 1,286 genotyped LRRK2 G2019S carriers and 109,154 non-carriers. Findings from the study, published today in the June 2024 issue of Brain, illustrate how DNA weaves together health, ancestry, and history.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ME:
- Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
- 23andMe reports Q4 EPS (43c) vs. (14c) last year
- 23andMe options imply 27.8% move in share price post-earnings
- ME Earnings this Week: How Will it Perform?
- Petros Pharmaceuticals launches U.S. distribution of STENDRA